Results 61 to 70 of about 589 (105)

Efficacy and safety comparison of hetrombopag and eltrombopag in children with cancer therapy-induced thrombocytopenia: a single-center retrospective study

Frontiers in Medicine
ObjectiveTo compare the efficacy and safety of hetrombopag and eltrombopag in children with cancer therapy-induced thrombocytopenia (CTIT), and to explore the clinical value of eltrombopag for this specific pediatric population given the current lack of ...
Li-Ting Yu, Min Zhang, Jia-Xin Zhang, An-An Zhang, Zhuo Wang, Dan He, Hao-Nan Li, Zhi-Ling Li, Yi-Jin Gao   +8 more
doaj   +1 more source

Plenary Abstracts Session & Oral Presentations

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

An Uncommon Association: Eltrombopag and Autoimmune Hepatitis

Case Reports in Hepatology
Autoimmune hepatitis (AIH) is an immunological disorder of the liver characterized by hepatic necroinflammation due to the break in self-tolerance to autoantigens. Many medications have been linked to drug induced AIH.
Fady Salama, Hassnain Syed, Nimish Thakral   +2 more
doaj   +1 more source

Eltrombopag-Induced Near-Fatal Hyperammonemic Encephalopathy - Case Report

Clinical Pediatric Hematology-Oncology
An 8-year-old girl with chronic immune thrombocytopenic purpura treated with eltrombopag presented with lactic acidosis and severe hyperammonemic encephalopathy necessitating hemofiltration. Genetic metabolic disorders associated with hyperammonemia were
Patrick Tomlinson, Barbara Paquete, Jessica Green, Bianca Maria Goffredo, Ehab Hamouda, Katya Bennett, Bernd C. Schwahn   +6 more
doaj   +1 more source

Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States

ClinicoEconomics and Outcomes Research, 2019
Gabriel Tremblay,1 Qayyim Said,2 Anuja Nidumolu Roy,2 Beilei Cai,2 Shan Ashton Garib,1 Jaclyn Hearnden,1 Anna Forsythe1 1Purple Squirrel Economics, New York, NY, USA; 2Novartis Pharmaceutical Corporation, East Hanover, NJ, USACorrespondence: Gabriel ...
Tremblay G, Said Q, Roy AN, Cai B, Ashton Garib S, Hearnden J, Forsythe A   +6 more
doaj  

Genetic variability in thrombopoietin receptor and GATA1 influences response to eltrombopag in dengue-induced thrombocytopenia

Scientific Reports
Integrating pharmacogenetic studies into clinical trials enhances personalized medicine by identifying genetic variations that influence drug efficacy and safety.
Mohammad Sayem, Razoan Al Rimon, Saruar Alam, Abdullah Al Saba, Mousumi Sanyal, Mohammad Sayem, Chowdhury Tamanna Tabassum, Md. Robed Amin, Sajib Chakraborty, Ahmedul Kabir, A. H. M. Nurun Nabi   +10 more
doaj   +1 more source

Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia

Therapeutics and Clinical Risk Management, 2019
Tamer A Elbedewy,1 Mohamed A Elsebaey,1 Samah A Elshweikh,1 Heba Elashry,2 Sherief Abd-Elsalam2 1Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt; 2Tropical Medicine Department, Faculty of Medicine, Tanta University ...
Elbedewy TA, Elsebaey MA, Elshweikh SA, Elashry H, Abd-Elsalam S   +4 more
doaj  

Some of the next articles are maybe not open access.

Related searches:

Eltrombopag

Drugs, 2009
Eltrombopag, an orally administered, small-molecule non-peptide thrombopoietin receptor agonist, selectively binds to the transmembrane domain of the thrombopoietin receptor on the surface of platelets, megakaryocytes and megakaryocyte precursor cells.
Karly P, Garnock-Jones, Susan J, Keam
openaire   +2 more sources